1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow High-Risk: new trials by email Literature Review of High-Risk trials Research Report on High-Risk
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma cyclophosphamide, NK cells, hu3F8 - Neuroblastoma, High-Risk | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 85 | 2016-01-05 | 2025-07-30 |
Neuroblastoma (1)
Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1) · Neuroectodermal Tumors (1) · Neuroectodermal Tumors, Primitive (1) · Neuroectodermal Tumors, Primitive, Peripheral (1)
Cyclophosphamide (1) · naxitamab (1)
Memorial Sloan Kettering Cancer Center (1)
United States (1)